Francesco Versace1, Elise M Stevens2, Jason D Robinson1, Yong Cui1, Menton M Deweese1, Jeffrey M Engelmann3, Charles E Green4, Maher Karam-Hage1, Cho Y Lam5, Jennifer A Minnix1, David W Wetter5, Paul M Cinciripini1. 1. Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Oklahoma Tobacco Research Center, Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK. 3. Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, WI. 4. Department of Pediatrics, The University of Texas-Houston Medical School, Houston, TX. 5. Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
Abstract
Introduction: Varenicline and bupropion are two effective smoking cessation pharmacotherapies. Researchers have hypothesized that they might be effective, in part, because they reduce cue reactivity and cue-induced cravings. Here, we used event-related potentials (ERPs) to directly measure brain responses to cigarette-related and other motivationally relevant images during a pharmacologically aided quit attempt. Methods: Smokers involved in a 12-week placebo-controlled double-blind clinical trial of smoking cessation medications (varenicline, bupropion, placebo) took part in the study. We assessed participants at two time points: 24 h (n = 140) and 4 weeks (n = 176) after the quit date. At both sessions, we measured the amplitude of the late positive potential (LPP), an ERP component reliably associated with motivational relevance, and self-reported tonic craving using the brief version of the Questionnaire of Smoking Urges (QSU-Brief). Results: At both sessions, emotional and cigarette-related images evoked significantly larger LPPs than neutral images. Neither drug type nor smoking abstinence altered this effect at either session. At both sessions, varenicline and bupropion significantly reduced self-reported tonic craving relative to the placebo condition. Conclusions: While both varenicline and bupropion reduced self-reported tonic craving, neither medication altered the amplitude of the LPP to cigarette-related or emotional pictures in smokers attempting to quit. These medications may influence abstinence by means other than by reducing neuroaffective responses to cigarette-related cues. Smokers should be prepared for the likelihood that even after several weeks of successful abstinence, once treatment ends, cigarette-related cues may remain motivationally relevant and trigger cravings that might lead to relapse. Implications: Bupropion and varenicline do not alter electrophysiological responses, as measured by the LPP, to cigarette-related and emotional images. These findings help explain why cigarette-related cues can trigger relapse when smoking cessation medication treatments end.
RCT Entities:
Introduction: Varenicline and bupropion are two effective smoking cessation pharmacotherapies. Researchers have hypothesized that they might be effective, in part, because they reduce cue reactivity and cue-induced cravings. Here, we used event-related potentials (ERPs) to directly measure brain responses to cigarette-related and other motivationally relevant images during a pharmacologically aided quit attempt. Methods: Smokers involved in a 12-week placebo-controlled double-blind clinical trial of smoking cessation medications (varenicline, bupropion, placebo) took part in the study. We assessed participants at two time points: 24 h (n = 140) and 4 weeks (n = 176) after the quit date. At both sessions, we measured the amplitude of the late positive potential (LPP), an ERP component reliably associated with motivational relevance, and self-reported tonic craving using the brief version of the Questionnaire of Smoking Urges (QSU-Brief). Results: At both sessions, emotional and cigarette-related images evoked significantly larger LPPs than neutral images. Neither drug type nor smoking abstinence altered this effect at either session. At both sessions, varenicline and bupropion significantly reduced self-reported tonic craving relative to the placebo condition. Conclusions: While both varenicline and bupropion reduced self-reported tonic craving, neither medication altered the amplitude of the LPP to cigarette-related or emotional pictures in smokers attempting to quit. These medications may influence abstinence by means other than by reducing neuroaffective responses to cigarette-related cues. Smokers should be prepared for the likelihood that even after several weeks of successful abstinence, once treatment ends, cigarette-related cues may remain motivationally relevant and trigger cravings that might lead to relapse. Implications: Bupropion and varenicline do not alter electrophysiological responses, as measured by the LPP, to cigarette-related and emotional images. These findings help explain why cigarette-related cues can trigger relapse when smoking cessation medication treatments end.
Authors: Francesco Versace; Jennifer A Minnix; Jason D Robinson; Cho Y Lam; Victoria L Brown; Paul M Cinciripini Journal: Addict Biol Date: 2010-12-23 Impact factor: 4.280
Authors: Jason D Robinson; Francesco Versace; Jeffery M Engelmann; Yong Cui; Aurelija Slapin; Robert Oum; Paul M Cinciripini Journal: Exp Clin Psychopharmacol Date: 2014-12-01 Impact factor: 3.157
Authors: Arthur L Brody; Mark A Mandelkern; Grace Lee; Erlyn Smith; Mary Sadeghi; Sanjaya Saxena; Murray E Jarvik; Edythe D London Journal: Psychiatry Res Date: 2004-04-30 Impact factor: 3.222
Authors: Freda Patterson; Christopher Jepson; Andrew A Strasser; James Loughead; Kenneth A Perkins; Ruben C Gur; Joseph M Frey; Steven Siegel; Caryn Lerman Journal: Biol Psychiatry Date: 2008-10-08 Impact factor: 13.382
Authors: Jason D Robinson; Yong Cui; Maher Karam-Hage; George Kypriotakis; Francesco Versace; Nassima Ait-Daoud Tiouririne; Robert M Anthenelli; Paul M Cinciripini Journal: Alcohol Clin Exp Res Date: 2022-01-31 Impact factor: 3.455